March 25, 2024
Daiichi Sankyo is looking at obtaining seven potentially game-changing indications for its cancer drug Enhertu (trastuzumab deruxtecan) by 2026, which would significantly expand the product’s patient population, oncology business head Ken Keller said on March 22. “There are seven potentially...read more